logo
Share SHARE
FONT-SIZE Plus   Neg

E-Therapeutics Granted Approval For Phase I Trials Of Anti-cancer Drug ETS2101

Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.

Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Tinder has launched a premium version of its popular dating app called Tinder Plus, which will cost users $9.99 each month, and double if they are over 30. In the US, Tinder Plus costs users $9.99 a month for users under 30 years, and $19.99 if users are over 30. Meanwhile, users under the age... European soft drinks and fruit juices bottler Refresco Gerber is pursuing initial public offering in Amsterdam to support its future growth. The firm which has been owned by private equity plans to list on Euronext. A new study shows that teens are able to easily buy e-cigarettes Online despite age restrictions. Teens could successfully have the nicotine-free e-cigarettes delivered to their doorsteps 94 percent of the time. Meanwhile, the sales of e-cigarettes, or vaping smokes, to young people under age 18 are already banned in a total of 41 states in the U.S.
comments powered by Disqus
Follow RTT